A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure

缬沙坦 医学 心力衰竭 射血分数 内科学 心脏病学 安慰剂 临床终点 血管紧张素受体 血管紧张素II 随机对照试验 血压 替代医学 病理
作者
Jay N. Cohn,Gianni Tognoni
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:345 (23): 1667-1675 被引量:2871
标识
DOI:10.1056/nejmoa010713
摘要

Actions of angiotensin II may contribute to the progression of heart failure despite treatment with currently recommended drugs. We therefore evaluated the long-term effects of the addition of the angiotensin-receptor blocker valsartan to standard therapy for heart failure.A total of 5010 patients with heart failure of New York Heart Association (NYHA) class II, III, or IV were randomly assigned to receive 160 mg of valsartan or placebo twice daily. The primary outcomes were mortality and the combined end point of mortality and morbidity, defined as the incidence of cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for at least four hours.Overall mortality was similar in the two groups. The incidence of the combined end point, however, was 13.2 percent lower with valsartan than with placebo (relative risk, 0.87; 97.5 percent confidence interval, 0.77 to 0.97; P=0.009), predominantly because of a lower number of patients hospitalized for heart failure; 455 (18.2 percent) in the placebo group and 346 (13.8 percent) in the valsartan group (P<0.001). Treatment with valsartan also resulted in significant improvements in NYHA class, ejection fraction, signs and symptoms of heart failure, and quality of life as compared with placebo (P<0.01). In a post hoc analysis of the combined end point and mortality in subgroups defined according to base-line treatment with angiotensin-converting-enzyme (ACE) inhibitors or beta-blockers, valsartan had a favorable effect in patients receiving neither or one of these types of drugs but an adverse effect in patients receiving both types of drugs.Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy. However, the post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a beta-blocker raises concern about the potential safety of this specific combination.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
1秒前
1秒前
3秒前
cldg发布了新的文献求助10
3秒前
3秒前
3秒前
3秒前
Epossible发布了新的文献求助10
3秒前
louis136116发布了新的文献求助10
5秒前
陈陈陈完成签到,获得积分20
5秒前
草莓完成签到,获得积分10
5秒前
风趣的老太应助lyt采纳,获得10
5秒前
wjx发布了新的文献求助10
6秒前
slow发布了新的文献求助10
6秒前
zjx发布了新的文献求助10
6秒前
杨自强发布了新的文献求助10
8秒前
8秒前
开心擎发布了新的文献求助10
8秒前
9秒前
9秒前
10秒前
bkagyin应助runner采纳,获得10
10秒前
Liu_Ci应助JJ的奇妙冒险采纳,获得10
10秒前
英姑应助毛豆爱睡觉采纳,获得10
11秒前
11秒前
NexusExplorer应助泡泡糖采纳,获得10
11秒前
11秒前
MgZn发布了新的文献求助10
11秒前
鲤鱼安青发布了新的文献求助10
12秒前
12秒前
彭于晏应助科研2121采纳,获得10
12秒前
领导范儿应助X欣采纳,获得10
13秒前
dong应助小柚子采纳,获得10
13秒前
zjq4302发布了新的文献求助10
13秒前
13秒前
14秒前
万能图书馆应助abcd采纳,获得10
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974943
求助须知:如何正确求助?哪些是违规求助? 3519467
关于积分的说明 11198482
捐赠科研通 3255728
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877261
科研通“疑难数据库(出版商)”最低求助积分说明 806224